Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
13.08. | Talaris Therapeutics GAAP EPS of -$0.90 | 1 | Seeking Alpha | ||
13.08. | Tourmaline Bio, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
13.08. | Tourmaline Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
13.08. | Tourmaline Bio, Inc.: Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights | 286 | GlobeNewswire (Europe) | - Reported positive topline results from the ongoing Phase 2 TRANQUILITY trial of pacibekitug in May 2025, demonstrating rapid, deep, and durable reductions in high-sensitivity C-reactive protein... ► Artikel lesen | |
06.06. | Tourmaline Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
27.05. | H.C. Wainwright maintains $50 target on Tourmaline Bio stock | 1 | Investing.com | ||
21.05. | Leerink raises Tourmaline Bio target to $54, affirms Outperform | 2 | Investing.com | ||
TOURMALINE BIO Aktie jetzt für 0€ handeln | |||||
21.05. | Tourmaline Bio stock holds $63 target post-Ph2 data | 3 | Investing.com | ||
21.05. | BMO maintains $35 target on Tourmaline Bio, sees overreaction | 1 | Investing.com | ||
20.05. | Tourmaline Bio shares fall on Phase 2 data; Schrödinger cuts staff | 46 | BioPharma Dive | ||
20.05. | Tourmaline Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
20.05. | Tourmaline Bio posts mid-stage data for anti-inflammatory agent | 1 | Seeking Alpha | ||
20.05. | Tourmaline Bio, Inc.: Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease | 219 | GlobeNewswire (Europe) | - Rapid, deep, and durable reductions in high-sensitivity C-reactive protein (hs-CRP) through Day 90 achieved across all pacibekitug arms with high statistical significance as compared to placebo... ► Artikel lesen | |
19.05. | Tourmaline Bio wird morgen Ergebnisse der Phase-2-Studie veröffentlichen | 1 | Investing.com Deutsch | ||
19.05. | Tourmaline Bio to reveal Phase 2 trial results tomorrow | 1 | Investing.com | ||
19.05. | Tourmaline Bio, Inc.: Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025 | 2 | GlobeNewswire (USA) | ||
02.05. | Talaris Therapeutics GAAP EPS of -$0.89 | 1 | Seeking Alpha | ||
02.05. | Tourmaline Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
02.05. | Tourmaline Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
02.05. | Tourmaline Bio, Inc.: Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights | 431 | GlobeNewswire (Europe) | - Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 - - Tourmaline... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 85,65 | +0,06 % | Paukenschlag beim Übernahmekandidaten! 100 %-Aktie BioNxt Solutions lässt BioNTech und Co. hinter sich! | Die Aktie von BioNxt ist endlich angesprungen. Anfang Juli hatten wir zuletzt auf die Chancen des kanadisch-deutschen Biowissenschaftsunternehmens hingewiesen. Seitdem ist die Aktie um fast 100 % gestiegen... ► Artikel lesen | |
EVOTEC | 6,000 | +0,03 % | Die Blaupause für KI-Medikamentenentwicklung: So nutzen Evotec, NetraMark Holdings und BioNTech die neuen Möglichkeiten | Die Pharmabranche befindet sich mitten in einer Revolution. Künstliche Intelligenz verkürzt die Wirkstoffentwicklung von Jahren auf Monate und steigert die Trefferquote dramatisch. Datengetriebene Prognosen... ► Artikel lesen | |
CUREVAC | 4,618 | +0,70 % | CureVac mit EILMELDUNG: Könnte die Aktie am Montag komplett einbrechen - Experten warnen!!! | ||
NOVAVAX | 6,377 | -0,20 % | H.C. Wainwright startet Coverage für Novavax mit "Buy"-Rating und Kursziel von 10 US-Dollar | ||
INFLARX | 1,364 | +0,66 % | InflaRx N.V.: InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update | INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by the end of September to early November 2025Phase 1/2 data announced by Staidson BioPharmaceuticals... ► Artikel lesen | |
CSL | 120,00 | 0,00 % | CSL LIMITED: Change of Director's Interest Notice x 9 | ||
COHERUS ONCOLOGY | 1,014 | +1,76 % | Coherus Oncology, Inc.: Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update | - LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 - - Data readouts for CHS-114 and casdozokitug on track for 1H 2026 - - Q2 2025 ending cash, cash equivalents and marketable... ► Artikel lesen | |
OCULAR THERAPEUTIX | 10,710 | +2,64 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company | BEDFORD, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), a biopharmaceutical company committed to redefining the retina experience, announced the launch... ► Artikel lesen | |
CYTOMX THERAPEUTICS | 1,706 | -2,40 % | CytomX: Wie geht's hier jetzt weiter? | Die Immuntherapie gegen Krebs entwickelt sich stetig weiter, und CytomX Therapeutics gehört zu den Unternehmen, die mit innovativen Ansätzen neue Maßstäbe setzen wollen. Die sogenannte "Probody"-Technologie... ► Artikel lesen | |
ORUKA THERAPEUTICS | 12,700 | +0,79 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | First patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026 ORKA-001 Phase 1 data and EVERLAST-A design to be presented at EADV in September 2025 ORKA-002 Phase... ► Artikel lesen | |
SPERO THERAPEUTICS | 1,688 | -4,42 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update | PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero... ► Artikel lesen | |
CIDARA THERAPEUTICS | 55,50 | -0,89 % | Cidara Therapeutics, Inc.: Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics... ► Artikel lesen | |
PALVELLA THERAPEUTICS | 43,600 | -9,17 % | Palvella Therapeutics Inc.: Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Phase 3 SELVA trial evaluating QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) for microcystic lymphatic malformations completed enrollment, exceeding enrollment target by over 25%; top-line... ► Artikel lesen | |
NEXTCURE | 5,070 | -1,74 % | NextCure, Inc. - 8-K, Current Report | ||
DIANTHUS THERAPEUTICS | 20,200 | 0,00 % | Dianthus Therapeutics, Inc.: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results | Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) Top-line MaGic results anticipated in September 2025 to be the first of three catalysts for the DNTH103... ► Artikel lesen |